logo
episode-header-image
Jul 16
35m 32s

409: Predicting biotech clinical trials ...

STAT
About this episode
On this week’s episode of "The Readout LOUD": The Kalshi prediction markets are coming for biotech, plus the controversy over an experimental Alzheimer’s disease treatment from Biogen. Kalshi, the maker of prediction markets, announced this week that it is expanding into biotech. Soon, you’ll be able to make bets on the outcomes of clinical trials and ... Show More
Up next
Jul 30
411: Capricor's data clash and a fugitive in the C-suite
Is the Food and Drug Administration taking inconsistent approaches to Duchenne muscular dystrophy drugs? How will a new batch of drug executives shake up their companies? And why is Adam talking to a recruiter?We discuss all that and more on this week’s episode of “The Readout LO ... Show More
36m 31s
Jul 23
410: A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
What does it take to develop a therapy for an ultra-rare disease? What are the allegations against a telehealth company that’s partnered with Novo Nordisk? And has a wanted fugitive been posing as a biotech executive? We discuss all that and more on this week’s episode of “The Re ... Show More
1h 4m
Jul 9
408: Whistleblower takes on health insurance and FDA commissioner candidates
Why does getting family health insurance through a job cost as much as buying a new car? How did a whistleblower take on an insurance contractor? And who might be the new Food and Drug Administration commissioner? We discuss all that and more on this week’s episode of “The Readou ... Show More
43m 58s
Recommended Episodes
Jan 2024
JP Morgan Healthcare Conference Highlights
Weight loss drugs are taking center spotlight, but other developing treatments could change how we live. Deidre Woollard caught up with Motley Fool biotech analyst Karl Thiel to discuss: - Biogen’s next shot at an Alzheimer’s treatment. - Why companies can’t “muscle their way” i ... Show More
26m 16s
Oct 2025
Big Pharma Breakout… And A Billionaire Boycott On Netflix 10/1/25
<p>Pharma stocks breaking out, as President Trump inks a drug pricing deal. What it means for the group, and how the broader health care sector is breathing a sigh of relief. Plus Elon Musk and some bingeing backlash. Why the billionaire is calling for customers to cancel their s ... Show More
41m 11s
May 2022
An Update on Healthcare Investing
Barron's senior managing editor Lauren R. Rublin and healthcare industry reporter Josh Nathan-Kazis discuss the outlook for healthcare stocks, and the latest news on Covid-19 treatments and vaccines. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information ab ... Show More
34m 28s
May 2025
Business Plans and Science Projects
Do you have a real relationship or just a non-binding letter of intent? (00:21) Nick Sciple and Mary Long discuss: - The S&P’s turnaround and inflation’s slow month-over-month decline. - A stock pop from a nuclear reactor company that doesn’t have a working nuclear reactor. - Pri ... Show More
31m 9s
Dec 2023
Pfizer’s Second Gut Punch Shows Pitfalls of Weight-Loss Pills
 Bloomberg News Health Reporter Madison Muller explains how Pfizer’s second weight-loss setback this year is a warning sign that breaking into the lucrative obesity market isn’t going to be easy. Cory Klippsten, CEO at Swan Bitcoin, shares his crypto outlook for 2024. Benjamin Wo ... Show More
42m 33s
Aug 2021
SEC to Demand More Transparency From China
Dr. Vino Palli, CEO of MiDoctor Urgent Care, discusses the Covid virus and vaccinations. Businessweek Technology Editor Joshua Brustein talks about his Businessweek Magazine story Afghanistan War Turns a U.S. Military Startup Into a Unicorn. Bloomberg News Financial Regulations R ... Show More
42m 46s
Dec 2023
Bristol’s $14 Billion Karuna Deal Highlights Race for New Drugs
Laura Chico, Biotechnology Research Analyst at Wedbush Securities and Bloomberg News US Deals Team Leader Matthew Monks share their thoughts on the Bristol Myers acquisition Karuna Therapeutics. John Mowrey, CIO at NFJ Investment Group, explains where to find value in the markets ... Show More
1h 2m
Nov 2025
Different Reads On The Consumer… And Pharma’s Obesity Drug Price Negotiations 11/5/25
<p>Earnings are filtering in, and companies are seeing a tale of two very different consumers. The group raising concerns about their customer base, and the names not seeing any slowdown. Plus Novo and Eli Lilly nearing a deal with the White house to lower obesity drug prices. Wh ... Show More
43m 47s
Aug 2024
AI-Powered Weapons Startup Raises $1.5B & Mounjaro Soars Past Wegovy
Episode 384: Neal and Toby chat about the round of funding for a startup that could transform the landscape of warfare by combining tech and military manufacturing. Then, upheaval in Bangladesh has global economies nervous about its impacts, especially in the fashion industry. Ne ... Show More
28m 8s
Listen to millions of songs and podcasts on Anghami